Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Public ClinicalTrials.gov record NCT00877006. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with advanced, indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL).
Study identification
- NCT ID
- NCT00877006
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 447 participants
Conditions and interventions
Conditions
Interventions
- bendamustine Drug
- rituximab Drug
- vincristine Drug
- prednisone Drug
- cyclophosphamide Drug
- doxorubicin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2009 (Type not available)
- Primary completion
- Mar 31, 2012 (Actual)
- Completion
- Mar 31, 2012 (Actual)
- Last update posted
- Feb 5, 2018
2009 – 2012
United States locations
- U.S. sites
- 79
- U.S. states
- 33
- U.S. cities
- 73
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 165 | Tucson | Arizona | — | — |
| Teva Investigational Site 167 | Little Rock | Arkansas | — | — |
| Teva Investigational Site 11 | Corona | California | — | — |
| Teva Investigational Site 21 | Fountain Valley | California | — | — |
| Teva Investigational Site 52 | Fountain Valley | California | — | — |
| Teva Investigational Site 64 | Fullerton | California | — | — |
| Teva Investigational Site 40 | Los Angeles | California | — | — |
| Teva Investigational Site 53 | Los Angeles | California | — | — |
| Teva Investigational Site 57 | San Diego | California | — | — |
| Teva Investigational Site 15 | Aurora | Colorado | — | — |
| Teva Investigational Site 155 | Denver | Colorado | — | — |
| Teva Investigational Site 5 | Fort Collins | Colorado | — | — |
| Teva Investigational Site 70 | New Britain | Connecticut | — | — |
| Teva Investigational Site 37 | Norwalk | Connecticut | — | — |
| Teva Investigational Site 67 | Southington | Connecticut | — | — |
| Teva Investigational Site 58 | Fort Myers | Florida | — | — |
| Teva Investigational Site 38 | Hollywood | Florida | — | — |
| Teva Investigational Site 23 | Jacksonville | Florida | — | — |
| Teva Investigational Site 65 | Lake Worth | Florida | — | — |
| Teva Investigational Site 156 | Miami | Florida | — | — |
| Teva Investigational Site 160 | Orlando | Florida | — | — |
| Teva Investigational Site 68 | Orlando | Florida | — | — |
| Teva Investigational Site 72 | Augusta | Georgia | — | — |
| Teva Investigational Site 50 | Columbus | Georgia | — | — |
| Teva Investigational Site 73 | Macon | Georgia | — | — |
| Teva Investigational Site 49 | Centralia | Illinois | — | — |
| Teva Investigational Site 48 | Chicago | Illinois | — | — |
| Teva Investigational Site 9 | Chicago | Illinois | — | — |
| Teva Investigational Site 14 | Normal | Illinois | — | — |
| Teva Investigational Site 24 | Beech Grove | Indiana | — | — |
| Teva Investigational Site 152 | Indianapolis | Indiana | — | — |
| Teva Investigational Site 31 | Iowa City | Iowa | — | — |
| Teva Investigational Site 63 | Waterloo | Iowa | — | — |
| Teva Investigational Site 47 | Wichita | Kansas | — | — |
| Teva Investigational Site 33 | Lexington | Kentucky | — | — |
| Teva Investigational Site 19 | Shreveport | Louisiana | — | — |
| Teva Investigational Site 43 | Augusta | Maine | — | — |
| Teva Investigational Site 74 | Lowell | Massachusetts | — | — |
| Teva Investigational Site 22 | Duluth | Minnesota | — | — |
| Teva Investigational Site 4 | Saint Louis Park | Minnesota | — | — |
| Teva Investigational Site 162 | Columbia | Missouri | — | — |
| Teva Investigational Site 157 | Kansas City | Missouri | — | — |
| Teva Investigational Site 29 | Morristown | New Jersey | — | — |
| Teva Investigational Site 46 | Albuquerque | New Mexico | — | — |
| Teva Investigational Site 8 | Rochester | New York | — | — |
| Teva Investigational Site 10 | Syracuse | New York | — | — |
| Teva Investigational Site 17 | Charlotte | North Carolina | — | — |
| Teva Investigational Site 151 | Durham | North Carolina | — | — |
| Teva Investigational Site 39 | Fargo | North Dakota | — | — |
| Teva Investigational Site 34 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 60 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 28 | Cleveland | Ohio | — | — |
| Teva Investigational Site 153 | Springfield | Oregon | — | — |
| Teva Investigational Site 59 | Bethlehem | Pennsylvania | — | — |
| Teva Investigational Site 44 | Danville | Pennsylvania | — | — |
| Teva Investigational Site 3 | Philadelphia | Pennsylvania | — | — |
| Teva Investigational Site 13 | Pittsburgh | Pennsylvania | — | — |
| Teva Investigational Site 7 | Pottstown | Pennsylvania | — | — |
| Teva Investigational Site 25 | Charleston | South Carolina | — | — |
| Teva Investigational Site 71 | Columbia | South Carolina | — | — |
| Teva Investigational Site 56 | Chattanooga | Tennessee | — | — |
| Teva Investigational Site 30 | Nashville | Tennessee | — | — |
| Teva Investigational Site 154 | Arlington | Texas | — | — |
| Teva Investigational Site 158 | Arlington | Texas | — | — |
| Teva Investigational Site 6 | El Paso | Texas | — | — |
| Teva Investigational Site 161 | Fort Worth | Texas | — | — |
| Teva Investigational Site 159 | San Antonio | Texas | — | — |
| Teva Investigational Site 166 | Sugar Land | Texas | — | — |
| Teva Investigational Site 2 | Salt Lake City | Utah | — | — |
| Teva Investigational Site 18 | Abingdon | Virginia | — | — |
| Teva Investigational Site 35 | Charlottesville | Virginia | — | — |
| Teva Investigational Site 164 | Norfolk | Virginia | — | — |
| Teva Investigational Site 54 | Richmond | Virginia | — | — |
| Teva Investigational Site 42 | Seattle | Washington | — | — |
| Teva Investigational Site 150 | Spokane | Washington | — | — |
| Teva Investigational Site 163 | Vancouver | Washington | — | — |
| Teva Investigational Site 66 | Morgantown | West Virginia | — | — |
| Teva Investigational Site 41 | Madison | Wisconsin | — | — |
| Teva Investigational Site 62 | Wausau | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00877006, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2018 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00877006 live on ClinicalTrials.gov.